Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

R. M. Silver, J. H. Warrick, M. B. Kinsella, L. S. Staudt, M. H. Baumann, C. Strange

Research output: Contribution to journalArticle

198 Scopus citations

Abstract

Fourteen patients with systemic sclerosis (SSc, scleroderma) and interstitial lung disease were treated with oral cyclophosphamide (1-2 mg/kg/day) and low dose prednisone (<10 mg/day). There was a significant improvement in FVC after 6 months compared to entry values (2.21 ± 0.19 l vs 2.03 ± 0.15 l, p < 0.02). Improvement was maintained at 12 months (2.27 ± 0.27 l, p < 0.05) and 18-24 months (2.60 + 0.28 l, p < 0.001). In 12 cases followed for 18-24 months, FVC was stable or improved. No significant improvement or decline was noted for the DLCO. Side effects included cytopenia (2), infection (1), and hemorrhagic cystitis (2), and one possible related malignancy. A controlled prospective trial of cyclophosphamide is warranted in patients with SSc and active interstitial lung disease.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalJournal of Rheumatology
Volume20
Issue number5
StatePublished - Jan 1 1993

    Fingerprint

Keywords

  • alveolitis
  • cyclophosphamide
  • pulmonary function
  • scleroderma
  • systemic sclerosis
  • treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Silver, R. M., Warrick, J. H., Kinsella, M. B., Staudt, L. S., Baumann, M. H., & Strange, C. (1993). Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. Journal of Rheumatology, 20(5), 838-844.